C. David Nicholson - 17 Jun 2025 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Reporting relationship: Director
Issuer ticker: ADVM
Reported as of: 17 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Jun 2025, 16:22:31 UTC
Prior SEC filing: 02 Apr 2025
Next SEC filing: 10 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Aneta Fergson, Attorney-in-Fact

Key filing fact

C. David Nicholson filed Form 4 for Adverum Biotechnologies, Inc. (ADVM) on 20 Jun 2025.

Key facts

This page summarizes C. David Nicholson's Form 4 filing for Adverum Biotechnologies, Inc. (ADVM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Jun 2025, 16:22.

Change

Previous filing in this sequence was filed on 02 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001636168 Primary reporting owner

Nicholson, C. David

Relationship: Director
Address: C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY
Signature: /s/ Aneta Fergson, Attorney-in-Fact
Signature date: 20 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADVM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +10,450
Change %
Price: $0.000000
Shares after: 10,450
Date: 17 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,450
Exercise price: $2.32
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest and become exercisable on the earlier of June 17, 2026 or the 2026 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.